Altheus Therapeutics, Inc.
Altheus is entering Phase 2 clinical trials with Zoenasa, a novel front-line combination treatment for ulcerative colitis.
- Stage Product In Development
- Industry Biotechnology
- Location Oklahoma City, OK, USA
- Currency USD
- Founded August 2007
- Employees 9
- Website altheustherapeutics.com
Company Summary
Altheus Therapeutics is developing Zoenasa as an innovative treatment for ulcerative colitis to meet the strong medical need for new therapies in this area. To build on its successful Phase 1 trial with Zoenasa, Altheus is raising $8 million to complete a Phase 2 proof-of-concept study and other development activities that will position the company for a joint-development agreement with a larger company and potential liquidity event.
Team
-
Dennis P SchaferPresident & Chief Executive Officer
An accomplished entrepreneur with 25 years’ experience in organizing and managing life science start-ups, Mr. Schafer has played leadership roles in a dozen start-ups, including BioCryst Pharmaceuticals, Coley Pharmaceuticals, and Aderis.
-
Richard F HartyFounder & Chief Science Officer
The former Chief of Gastroenterology at the OU Health Sciences Center, Dr. Harty is an internationally recognized practitioner, educator, and researcher.
-
Dayton T ReardanChief Operating Officer
Former VP Regulatory Affairs at Orphan Medical, Dr. Reardan is nationally recognized for his expertise in developing orphan drugs and other products with abbreviated development paths.
Advisors
-
Douglas A. Branch, JD (Phillips Murrah)LawyerUnconfirmedCindy Sewell Dunlop; Cole & ReedAccountantUnconfirmed
Previous Investors
-
Prolog Ventures, i2e Seed Fund,UnconfirmedOklahoma Life Sciences Fund II,UnconfirmedOklahoma Equity Partners, Chickasaw Soliris,Unconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.